The era of daily pill-taking for schizophrenia may be drawing to a close. In February 2026, the FDA accepted Teva Pharmaceuticals’ New Drug Application for TEV-749, an investigational once-monthly subcutaneous injection of olanzapine that could replace the daily oral versions millions of patients currently rely on. If approved, TEV-749 would join a growing class of long-acting injectable antipsychotics that are fundamentally changing how schizophrenia is managed — not by inventing new molecules, but by delivering proven ones in ways that work with human behavior rather than against it. This shift matters enormously for patients and caregivers alike.
Schizophrenia affects roughly 1 in 100 people worldwide, and medication non-adherence remains one of the single biggest obstacles to stable, long-term outcomes. A patient who forgets a daily pill — or chooses to skip it because they feel better — faces a real risk of relapse, hospitalization, and cognitive decline. Monthly injections sidestep that problem entirely. Beyond TEV-749, other breakthroughs are reshaping the treatment landscape, including the FDA’s approval of Cobenfy, the first schizophrenia drug to work through an entirely new mechanism in decades, and Amneal Pharmaceuticals’ recently approved once-monthly risperidone injection. This article examines each of these developments, what they mean for patients and families, and what limitations still remain.
Table of Contents
- What Makes a Monthly Injection a Real Breakthrough for Schizophrenia Medication?
- Why TEV-749 Could Eliminate a Dangerous Post-Injection Requirement
- Amneal’s Risperidone Injection and the Expanding Injectable Landscape
- How Cobenfy Represents a Completely Different Kind of Breakthrough
- What Patients and Caregivers Should Know About Switching Medications
- The Role of Long-Acting Injectables in Reducing Hospitalizations
- What the Next Few Years Could Look Like for Schizophrenia Treatment
- Conclusion
- Frequently Asked Questions
What Makes a Monthly Injection a Real Breakthrough for Schizophrenia Medication?
To understand why a monthly shot is such a significant advance, consider the daily reality of schizophrenia treatment. most antipsychotics require one or two pills every single day, without exception. But schizophrenia itself can impair insight — many patients genuinely do not believe they are ill, a neurological symptom called anosognosia. Asking someone who doesn’t think they’re sick to take a pill every morning is a recipe for inconsistency. Studies have consistently shown that within a year of starting oral antipsychotics, a substantial proportion of patients partially or fully stop taking them. Long-acting injectables like TEV-749 change the equation. A single subcutaneous injection administered once a month by a healthcare provider guarantees 30 days of consistent medication levels in the bloodstream.
There is no daily decision to make, no pill to forget, no prescription to refill every few weeks. For caregivers — often aging parents or partners already managing their own health challenges — this removes a major source of daily stress and conflict. The injection schedule also creates a built-in monthly check-in with a clinician, which means emerging problems get caught earlier. The existing long-acting injectable market has been growing for years. Abilify Asimtufii, an aripiprazole formulation, already offers dosing every two months. Erzofri, another FDA-approved long-acting treatment, serves patients with both schizophrenia and schizoaffective disorder. What sets TEV-749 apart is the specific drug it delivers — olanzapine — and a critical safety advantage over the olanzapine injectable already on the market.
Why TEV-749 Could Eliminate a Dangerous Post-Injection Requirement
Olanzapine is one of the most effective antipsychotics available, particularly for patients who haven’t responded well to other medications. But the existing long-acting injectable form of olanzapine, marketed as Zyprexa Relhypv, comes with a serious catch: every single injection requires three hours of post-injection monitoring in a certified healthcare facility. This is because the current formulation carries a risk of post-injection delirium/sedation syndrome, a potentially dangerous reaction where the drug enters the bloodstream too quickly and causes severe sedation, confusion, or even loss of consciousness. that three-hour observation requirement has severely limited adoption. Many clinics simply cannot dedicate the space, staff, and time to watch a patient for three hours after every monthly visit. Patients who live in rural areas or who lack reliable transportation face even greater barriers.
In practice, this means one of the most effective antipsychotics has been largely unavailable in long-acting injectable form for the patients who need it most. TEV-749’s Phase 3 SOLARIS trial showed no evidence for the need for post-injection monitoring — a finding that, if confirmed through the regulatory process, would be transformative. However, it is important to note that TEV-749 has not yet been approved by any regulatory authority. The FDA has accepted the application for review, but acceptance is not approval. Patients and families should not discontinue current treatment plans in anticipation of this drug becoming available. The FDA’s decision is still pending, and the timeline for a final ruling has not been publicly disclosed as of early 2026.
Amneal’s Risperidone Injection and the Expanding Injectable Landscape
While TEV-749 awaits its FDA decision, another monthly injectable has already crossed the finish line. Amneal Pharmaceuticals received FDA approval for its risperidone extended-release injectable suspension, a once-monthly subcutaneous injection approved for both schizophrenia and maintenance treatment of bipolar I disorder. The product received 180-day exclusivity under the FDA’s Competitive Generic Therapy designation, and Amneal expected to launch by the end of 2025. Risperidone is a well-established antipsychotic with decades of clinical use, and its side effect profile is familiar to most psychiatrists. Making it available as a monthly subcutaneous injection — rather than a daily pill or the older intramuscular formulation — lowers the barrier to adherence for a large patient population.
For individuals managing both schizophrenia and bipolar disorder, the dual indication is particularly meaningful, since it reduces the number of separate medications they need to track. The practical difference between subcutaneous and intramuscular injections is worth noting. Subcutaneous shots are given just under the skin, typically in the abdomen or upper arm, using a shorter needle. They are generally less painful and can be administered more quickly than intramuscular injections, which require a longer needle inserted into muscle tissue. This distinction may seem minor, but for patients who will receive injections every month for years or even decades, comfort and convenience compound over time.
How Cobenfy Represents a Completely Different Kind of Breakthrough
Not all advances in schizophrenia treatment are about how drugs are delivered. In September 2024, the FDA approved Cobenfy, developed by Bristol Myers Squibb, and it represents something that hasn’t happened in schizophrenia pharmacology in over 70 years: a genuinely new mechanism of action. Every antipsychotic approved since chlorpromazine in the 1950s has worked primarily by blocking dopamine receptors. Cobenfy does not. Instead, it targets muscarinic receptors, opening an entirely different therapeutic pathway. This matters because dopamine-blocking drugs, while effective for many patients, come with well-known drawbacks. Weight gain, metabolic syndrome, movement disorders like tardive dyskinesia, and emotional blunting are common side effects that drive many patients to stop treatment.
Cobenfy’s muscarinic mechanism offers the possibility of treating psychotic symptoms without some of these dopamine-related burdens. However, Cobenfy is an oral medication — a daily pill — not an injectable. So while it solves one problem (side effect profile), it doesn’t address the adherence challenge that long-acting injectables target. The tradeoff is real and worth discussing with a prescriber. A patient who tolerates olanzapine well but struggles to take daily pills might benefit most from TEV-749, if approved. A patient who takes pills reliably but suffers from metabolic side effects on dopamine-blocking drugs might be a better candidate for Cobenfy. There is no single best option — only the best option for a given individual’s circumstances, symptoms, and history.
What Patients and Caregivers Should Know About Switching Medications
The excitement around new treatment options can create pressure — from patients, families, or even clinicians — to switch medications prematurely. This is a real risk. Any change in antipsychotic medication should be approached carefully, ideally with a gradual cross-taper supervised by a psychiatrist who knows the patient’s history. Abruptly stopping one antipsychotic to start another can trigger withdrawal symptoms, rebound psychosis, or a relapse that takes months to stabilize. For dementia caregivers who also support a family member with schizophrenia, this caution is doubly important. Older adults with schizophrenia may have been stable on the same oral medication for years or even decades. Switching to an injectable formulation offers real benefits, but the transition period itself introduces uncertainty.
Blood levels of the new drug take time to reach steady state, and the old drug needs to be tapered appropriately. This is not a weekend project — it requires planning, monitoring, and patience. There is also the question of access and cost. Long-acting injectables tend to be significantly more expensive than generic oral pills. Insurance coverage varies widely, and prior authorization requirements can delay treatment initiation. Patients in the Medicare Part D coverage gap, or those with Medicaid in states with restrictive formularies, may face obstacles that have nothing to do with the drug’s clinical merits. Before pursuing a switch, it is worth having a frank conversation with both the prescribing physician and the insurance provider about what will actually be covered.
The Role of Long-Acting Injectables in Reducing Hospitalizations
One of the strongest arguments for monthly injectables comes from hospital readmission data. When patients stop taking oral antipsychotics, the resulting relapses frequently lead to emergency psychiatric hospitalizations — events that are traumatic for patients, devastating for families, and enormously expensive for the healthcare system. Long-acting injectables have been shown in real-world studies to reduce hospitalization rates compared to oral formulations, precisely because they remove the daily adherence variable.
Consider a patient who has been hospitalized three times in two years due to medication non-adherence. Each hospitalization might last one to three weeks and cost tens of thousands of dollars. Switching that patient to a monthly injectable that costs a few thousand dollars per year can be not only clinically superior but also cost-effective from a systems perspective. This is why many state Medicaid programs and managed care organizations have begun prioritizing access to long-acting injectables, despite their higher per-dose cost.
What the Next Few Years Could Look Like for Schizophrenia Treatment
The convergence of new delivery methods and new mechanisms of action suggests that schizophrenia treatment is entering its most dynamic period in decades. If TEV-749 gains FDA approval, patients will have access to monthly olanzapine without the burdensome post-injection monitoring that has limited the current formulation. Combined with options like Abilify Asimtufii’s every-two-month dosing, the trajectory is clearly moving toward less frequent, more convenient treatment schedules.
It is not difficult to imagine quarterly or even semi-annual formulations emerging within the next five to ten years. Meanwhile, Cobenfy’s approval has validated the muscarinic receptor pathway, and multiple pharmaceutical companies are now exploring similar non-dopamine mechanisms. If these next-generation drugs can eventually be formulated as long-acting injectables, the field could see treatments that are both mechanistically novel and adherence-friendly — addressing the two biggest limitations of current care simultaneously. For patients and families living with schizophrenia today, the message is cautiously optimistic: the treatment landscape is changing faster than it has in a generation, and the changes are grounded in real science, not hype.
Conclusion
The daily pill has been the default delivery method for schizophrenia medication for over half a century, and its limitations are well documented. Monthly injectables like TEV-749, Amneal’s risperidone formulation, and existing options like Abilify Asimtufii and Erzofri offer a fundamentally different approach — one that works with the realities of a condition that often impairs the very insight needed to maintain daily treatment. Cobenfy adds another dimension by proving that effective antipsychotics don’t have to work through dopamine blockade, potentially sparing patients from some of the most burdensome side effects in psychiatry.
For caregivers navigating both dementia and schizophrenia in their families, these developments bring practical hope. But hope should be paired with careful planning. Talk to your loved one’s psychiatrist about whether a long-acting injectable might be appropriate, ask about insurance coverage before making assumptions, and resist the urge to change everything at once. The best medication is the one that gets taken consistently, works effectively, and causes the fewest problems — and for the first time in a long while, there are genuinely new options to evaluate.
Frequently Asked Questions
Is TEV-749 available now?
No. As of early 2026, TEV-749 has not been approved by any regulatory authority. The FDA accepted Teva’s New Drug Application in February 2026, which means the application is under review, but no approval decision has been made yet.
What is the difference between TEV-749 and the existing olanzapine injection (Zyprexa Relhypv)?
The key difference is safety monitoring. Zyprexa Relhypv requires three hours of post-injection observation at a certified facility due to the risk of post-injection delirium/sedation syndrome. The Phase 3 SOLARIS trial for TEV-749 showed no evidence that post-injection monitoring would be needed, which could dramatically improve accessibility if the FDA agrees.
Does Cobenfy replace traditional antipsychotics?
Cobenfy is not a replacement for all antipsychotics. It works through a different mechanism — targeting muscarinic receptors instead of dopamine receptors — and may be appropriate for patients who experience significant side effects from dopamine-blocking drugs. It is a daily oral pill, so it does not address adherence challenges the way injectables do.
Are monthly injections painful?
TEV-749 and Amneal’s risperidone injection are both subcutaneous, meaning they use a shorter needle injected just under the skin. Most patients describe mild discomfort similar to a routine vaccination. Injection site reactions are possible but generally mild.
Will insurance cover long-acting injectable antipsychotics?
Coverage varies significantly by plan and state. Many commercial insurers and Medicaid programs cover long-acting injectables, but prior authorization is often required. It is essential to verify coverage with your specific insurance provider before initiating treatment.
Can someone with both dementia and schizophrenia use these new treatments?
Antipsychotic use in dementia patients carries an FDA black box warning due to increased risk of death in elderly patients with dementia-related psychosis. Any use of antipsychotics in this population requires careful risk-benefit analysis with a qualified psychiatrist. These new formulations do not change that fundamental safety concern.
